Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal study of Brilacidin for Oral Mucositis

Trial Profile

A pivotal study of Brilacidin for Oral Mucositis

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Brilacidin (Primary)
  • Indications Stomatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Innovation Pharmaceuticals
  • Most Recent Events

    • 02 Jan 2019 According to an Innovation Pharmaceuticals media release, the company expects to initiate this study in 2019.
    • 17 Dec 2018 According to a media release, the company and the US FDA have completed an End-of-Phase 2 meeting concerning the continuing development of Brilacidin oral rinse to decrease the incidence of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.
    • 23 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top